Comparison · NCT01298570-deaths
Arm A vs Arm B: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm A vs Arm B: deaths from any cause. Trial comparisons, record NCT01298570-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01298570-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.933 | 0.874 | 0.966 | wilson | |
| Risk in group 2 | 0.967 | 0.888 | 0.991 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0339 | -0.0978 | 0.0516 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.965 | 0.903 | 1.03 | log | |
| Odds ratio, group 1 over group 2 | 0.475 | 0.0976 | 2.31 | log | |
| Number needed to treat, for one fewer death from any cause on Arm A than on Arm B | 29.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm A | regorafenib 160 mg + FOLFIRI~Regorafenib (BAY 73-4506): Regorafenib, 160 mg, PO, daily, per 7 day cycle~FOLFIRI: FOLFIRI (Irinotecan,180 mg/m2 IV over 90 minutes; 5-Fluorouracil l400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours; Leucovorin 200-400c mg/m2 IV over 2 hours) Day 1 and Day 15 of each 28 day cycle. | 112 | 120 | EG000 |
| Group 2 | Arm B | Placebo + FOLFIRI~Placebo: Placebo, oral administration, Days 4-10 and Days 18-24 of 28 day cycle +~FOLFIRI: FOLFIRI (Irinotecan,180 mg/m2 IV over 90 minutes; 5-Fluorouracil l400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours; Leucovorin 200-400c mg/m2 IV over 2 hours) Day 1 and Day 15 of each 28 day cycle. | 59 | 61 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
Source ClinicalTrials.gov
Trial
- Title
- Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer
- NCT number
- NCT01298570
- Phases
- PHASE2
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- Regorafenib (BAY 73-4506), FOLFIRI, Placebo, FOLFIRI
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Results first posted
- 2018-02-28
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01298570?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01298570-deaths